VEGFA and ovarian carcinoma: VEGF-targeted therapy is clearly an active approach in ovarian cancer (at least in combination with chemotherapy) and other anti-angiogenic agents have been investigated in this setting including pazopanib (6), cedirinib (7), nintedanib (8), aflibercept (9), trebananib (10), sunitinib (11), sorafenib (12), and (PDGFR) imatinib (13).